Topical administration of cisplatin in far-advanced squamous cell carcinoma of the head and neck

Cisplatinum and interstitial laser therapy for advanced head and neck cancer: A preclinical study

“…Despite encouraging tumor response rates after treatment with CDDP and other chemotherapeutic agents, the lack of significant improvement in survival of patients with advanced head and neck cancer suggests a need for improved drug delivery to the target tumor [6]. Intravenous drug delivery to tumors is compromised by systemic toxicity and reduced uptake due to local devascularization after surgery or radiation therapy, as well as high interstitial pressure from rapid tumor growth [6]. Intralesional injections of free CDDP have been compromised by an inability to maintain high intratumor drug levels for a time interval sufficient to maximize intracellular uptake [7,8].…”

“…Although this drug has become one of the most widely used cancer chemotherapeutic agents, renal toxicity and other side effects have limited its application [5]. Despite encouraging tumor response rates after treatment with CDDP and other chemotherapeutic agents, the lack of significant improvement in survival of patients with advanced head and neck cancer suggests a need for improved drug delivery to the target tumor [6]. Intravenous drug delivery to tumors is compromised by systemic toxicity and reduced uptake due to local devascularization after surgery or radiation therapy, as well as high interstitial pressure from rapid tumor growth [6].…”

Cisplatinum and interstitial laser therapy for advanced head and neck cancer: A preclinical study

“…Despite encouraging tumor response rates after treatment with CDDP and other chemotherapeutic agents, the lack of significant improvement in survival of patients with advanced head and neck cancer suggests a need for improved drug delivery to the target tumor [6]. Intravenous drug delivery to tumors is compromised by systemic toxicity and reduced uptake due to local devascularization after surgery or radiation therapy, as well as high interstitial pressure from rapid tumor growth [6]. Intralesional injections of free CDDP have been compromised by an inability to maintain high intratumor drug levels for a time interval sufficient to maximize intracellular uptake [7,8].…”

“…Although this drug has become one of the most widely used cancer chemotherapeutic agents, renal toxicity and other side effects have limited its application [5]. Despite encouraging tumor response rates after treatment with CDDP and other chemotherapeutic agents, the lack of significant improvement in survival of patients with advanced head and neck cancer suggests a need for improved drug delivery to the target tumor [6]. Intravenous drug delivery to tumors is compromised by systemic toxicity and reduced uptake due to local devascularization after surgery or radiation therapy, as well as high interstitial pressure from rapid tumor growth [6].…”

Laser and cisplatinum for treatment of human squamous cell carcinoma

“…2 and 3). This was expected because drug delivery to tumors is compromised by high interstitial pressure from rapid tumor growth and inability to maintain high intratumor drug levels for a time interval sufficient to maximize intracellular uptake 7,9,10 . A Phase III multicenter study of intralesional injection with cisplatin in 45 patients with accessable and measurable advanced superficial malignant tumors indicated that the incidence of adverse effects and clinical toxicities was minimal after administration of CDDP in a bovine collagen gel.…”

“…Balb/c nu/nu mice 6 to 8 weeks old were maintained in filter‐top sterile plastic cages. P3 tumor cells were detached from monolayer cultures with 0.25% trypsin, and viable cells counted in trypan blue using a hemocytometer slide before subcutaneous injection in the posterior flank at 1 × 10 7 cells/0.1 mL of RPMI medium. Palpable tumors were present in 95% of the animals within 7 to 10 days.…”

Intratumoral cisplatin/epinephrine gel in advanced head and neck cancer: A multicenter, randomized, double‐blind, phase III study in North America

“…[5][6][7] Low responses of locally recurrent tumors to systemic chemotherapy may be partially attributed to patient noncompliance, 8 suboptimal drug delivery to inadequately perfused regions of tumors, 9 or to disrupted vascular architecture of the region after surgery and radiotherapy. 10 To achieve high intratumoral drug concentrations and minimize systemic exposure, regional (eg, intraarterial) [11][12][13][14] and local (eg, topical creams, intratumoral injections, or implantable polymers) routes of administration have been evaluated with a number of agents, including fluorouracil, 15 bleomycin, 16,17 cisplatin, 18,19 immunomodulators, 20,21 and gene therapy. 22 Of these locoregional delivery routes, injection of an antineoplastic agent into a tumor is the simplest and most direct approach for treatment of accessible solid tumors.…”

Cisplatinum and interstitial laser therapy for advanced head and neck cancer: A preclinical study

“…Despite encouraging tumor response rates after treatment with CDDP and other chemotherapeutic agents, the lack of significant improvement in survival of patients with advanced head and neck cancer suggests a need for improved drug delivery to the target tumor [6]. Intravenous drug delivery to tumors is compromised by systemic toxicity and reduced uptake due to local devascularization after surgery or radiation therapy, as well as high interstitial pressure from rapid tumor growth [6]. Intralesional injections of free CDDP have been compromised by an inability to maintain high intratumor drug levels for a time interval sufficient to maximize intracellular uptake [7,8].…”

“…Although this drug has become one of the most widely used cancer chemotherapeutic agents, renal toxicity and other side effects have limited its application [5]. Despite encouraging tumor response rates after treatment with CDDP and other chemotherapeutic agents, the lack of significant improvement in survival of patients with advanced head and neck cancer suggests a need for improved drug delivery to the target tumor [6]. Intravenous drug delivery to tumors is compromised by systemic toxicity and reduced uptake due to local devascularization after surgery or radiation therapy, as well as high interstitial pressure from rapid tumor growth [6].…”

Laser and cisplatinum for treatment of human squamous cell carcinoma

“…2 and 3). This was expected because drug delivery to tumors is compromised by high interstitial pressure from rapid tumor growth and inability to maintain high intratumor drug levels for a time interval sufficient to maximize intracellular uptake 7,9,10 . A Phase III multicenter study of intralesional injection with cisplatin in 45 patients with accessable and measurable advanced superficial malignant tumors indicated that the incidence of adverse effects and clinical toxicities was minimal after administration of CDDP in a bovine collagen gel.…”

“…Balb/c nu/nu mice 6 to 8 weeks old were maintained in filter‐top sterile plastic cages. P3 tumor cells were detached from monolayer cultures with 0.25% trypsin, and viable cells counted in trypan blue using a hemocytometer slide before subcutaneous injection in the posterior flank at 1 × 10 7 cells/0.1 mL of RPMI medium. Palpable tumors were present in 95% of the animals within 7 to 10 days.…”

Intratumoral cisplatin/epinephrine gel in advanced head and neck cancer: A multicenter, randomized, double‐blind, phase III study in North America

“…[5][6][7] Low responses of locally recurrent tumors to systemic chemotherapy may be partially attributed to patient noncompliance, 8 suboptimal drug delivery to inadequately perfused regions of tumors, 9 or to disrupted vascular architecture of the region after surgery and radiotherapy. 10 To achieve high intratumoral drug concentrations and minimize systemic exposure, regional (eg, intraarterial) [11][12][13][14] and local (eg, topical creams, intratumoral injections, or implantable polymers) routes of administration have been evaluated with a number of agents, including fluorouracil, 15 bleomycin, 16,17 cisplatin, 18,19 immunomodulators, 20,21 and gene therapy. 22 Of these locoregional delivery routes, injection of an antineoplastic agent into a tumor is the simplest and most direct approach for treatment of accessible solid tumors.…”

Cisplatinum and interstitial laser therapy for advanced head and neck cancer: A preclinical study

“…Despite encouraging tumor response rates after treatment with CDDP and other chemotherapeutic agents, the lack of significant improvement in survival of patients with advanced head and neck cancer suggests a need for improved drug delivery to the target tumor [6]. Intravenous drug delivery to tumors is compromised by systemic toxicity and reduced uptake due to local devascularization after surgery or radiation therapy, as well as high interstitial pressure from rapid tumor growth [6]. Intralesional injections of free CDDP have been compromised by an inability to maintain high intratumor drug levels for a time interval sufficient to maximize intracellular uptake [7,8].…”

“…Although this drug has become one of the most widely used cancer chemotherapeutic agents, renal toxicity and other side effects have limited its application [5]. Despite encouraging tumor response rates after treatment with CDDP and other chemotherapeutic agents, the lack of significant improvement in survival of patients with advanced head and neck cancer suggests a need for improved drug delivery to the target tumor [6]. Intravenous drug delivery to tumors is compromised by systemic toxicity and reduced uptake due to local devascularization after surgery or radiation therapy, as well as high interstitial pressure from rapid tumor growth [6].…”

Laser and cisplatinum for treatment of human squamous cell carcinoma

“…2 and 3). This was expected because drug delivery to tumors is compromised by high interstitial pressure from rapid tumor growth and inability to maintain high intratumor drug levels for a time interval sufficient to maximize intracellular uptake 7,9,10 . A Phase III multicenter study of intralesional injection with cisplatin in 45 patients with accessable and measurable advanced superficial malignant tumors indicated that the incidence of adverse effects and clinical toxicities was minimal after administration of CDDP in a bovine collagen gel.…”

“…Balb/c nu/nu mice 6 to 8 weeks old were maintained in filter‐top sterile plastic cages. P3 tumor cells were detached from monolayer cultures with 0.25% trypsin, and viable cells counted in trypan blue using a hemocytometer slide before subcutaneous injection in the posterior flank at 1 × 10 7 cells/0.1 mL of RPMI medium. Palpable tumors were present in 95% of the animals within 7 to 10 days.…”

Intratumoral cisplatin/epinephrine gel in advanced head and neck cancer: A multicenter, randomized, double‐blind, phase III study in North America

“…[5][6][7] Low responses of locally recurrent tumors to systemic chemotherapy may be partially attributed to patient noncompliance, 8 suboptimal drug delivery to inadequately perfused regions of tumors, 9 or to disrupted vascular architecture of the region after surgery and radiotherapy. 10 To achieve high intratumoral drug concentrations and minimize systemic exposure, regional (eg, intraarterial) [11][12][13][14] and local (eg, topical creams, intratumoral injections, or implantable polymers) routes of administration have been evaluated with a number of agents, including fluorouracil, 15 bleomycin, 16,17 cisplatin, 18,19 immunomodulators, 20,21 and gene therapy. 22 Of these locoregional delivery routes, injection of an antineoplastic agent into a tumor is the simplest and most direct approach for treatment of accessible solid tumors.…”